Compare VREX & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VREX | ENTA |
|---|---|---|
| Founded | 2016 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 483.7M | 407.5M |
| IPO Year | N/A | 2013 |
| Metric | VREX | ENTA |
|---|---|---|
| Price | $12.17 | $14.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $16.67 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 356.4K | 290.8K |
| Earning Date | 02-05-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $844,600,000.00 | $65,324,000.00 |
| Revenue This Year | $4.79 | $0.99 |
| Revenue Next Year | $4.15 | $0.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.14 | N/A |
| 52 Week Low | $6.76 | $4.09 |
| 52 Week High | $15.46 | $15.34 |
| Indicator | VREX | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 61.87 | 61.51 |
| Support Level | $11.71 | $14.07 |
| Resistance Level | $12.00 | $15.28 |
| Average True Range (ATR) | 0.33 | 0.75 |
| MACD | 0.08 | -0.08 |
| Stochastic Oscillator | 91.26 | 52.94 |
Varex Imaging Corp designs and manufactures X-ray imaging components. It operates in two segments Medical and Industrial. The Medical segment, which is the key revenue driver, designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, digital detectors and accessories, generators, and heat exchangers among other products. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high-voltage connectors, and coolers. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA) and the rest from the Americas and Asia Pacific region.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.